The 2017 GI Cancers Symposium concludes another year of enlightening discourse, instructive education, and fruitful interaction among the 3,500 attendees. Read on for a snapshot of the top research presented at the meeting.
To begin to tease apart the marked heterogeneity of colorectal cancer (CRC), recent efforts have focused on the “sidedness” of disease. New analyses are now building on this work, both in metastatic and earlier-stage disease, to provide greater insight into the sidedness issue.
Investigators dug back into the Adenoma Prevention With Celecoxib (APC) tissue archives to identify biomarkers that distinguish those individuals at high risk for colorectal adenomas who stand to derive greatest benefit from celecoxib chemoprevention.
Findings from a prospective phase II trial suggest that treatment with cabozantinib monotherapy confers marked clinical benefit in patients with progressive, well-differentiated neuroendocrine tumors—lesions that historically are difficult to treat given their chemoresistant nature.
Inhibiting both BRAF and EGFR within the MAPK pathway proves promising for staunching tumor growth in select cases of metastatic colorectal cancer based on interim results of the phase II SWOG S1406 trial.
Preliminary data from the phase I/II CheckMate 040 study of nivolumab suggest that the anti-PD-1 antibody is both active and well tolerated when given as first- or second-line monotherapy to patients with advanced HCC.
Results of this small feasibility study suggest that stereotactic body radiation therapy may be an alternative bridging option for patients with locally advanced disease—one that can be performed in the outpatient setting while potentially causing minimal major morbidity.
Level I evidence supporting the benefit of adjuvant therapy in localized biliary cancer remains elusive based on the negative results of the PRODIGE 12–ACCORD 18 trial that compared GEMOX versus surveillance.
Nivolumab represents the first immunotherapy in phase III analyses to significantly improve OS, PFS, and ORR in patients with advanced gastric or gastroesophageal junction cancer, fulfilling a dire need for effective salvage therapy for a subgroup of patients.
This phase II trial demonstrates that using PET imaging following initial induction chemotherapy to assess early response can maximize pCR rates in esophageal adenocarcinoma by signaling the need to switch from ineffective to alternative chemotherapy during preoperative chemoradiation.
Drs. Young and Chau review several early-phase studies on combination immunotherapy treatments for GI cancers and what these studies have uncovered about the certain tumor types that are responsive and those that are poorly immunogenic.
Dr. Jorge Gallardo and colleagues discuss the epidemiology of esophageal, gastric, liver, gallbladder, pancreatic, colon, and rectal cancers in Chile and how the country’s changing demographics across the past 20 years have increased cancer mortality rates.